BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 33579424)

  • 1. Atypical immunometabolism and metabolic reprogramming in liver cancer: Deciphering the role of gut microbiome.
    Golonka RM; Vijay-Kumar M
    Adv Cancer Res; 2021; 149():171-255. PubMed ID: 33579424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response.
    Delaune V; Orci LA; Lacotte S; Peloso A; Schrenzel J; Lazarevic V; Toso C
    Expert Opin Biol Ther; 2018 Oct; 18(10):1061-1071. PubMed ID: 30173562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut microbiota: A new piece in understanding hepatocarcinogenesis.
    Zhou A; Tang L; Zeng S; Lei Y; Yang S; Tang B
    Cancer Lett; 2020 Apr; 474():15-22. PubMed ID: 31917160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome.
    Temraz S; Nassar F; Kreidieh F; Mukherji D; Shamseddine A; Nasr R
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut microbiome in HCC - Mechanisms, diagnosis and therapy.
    Schwabe RF; Greten TF
    J Hepatol; 2020 Feb; 72(2):230-238. PubMed ID: 31954488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microecological regulation in HCC therapy: Gut microbiome enhances ICI treatment.
    Liu X; Li S; Wang L; Ma K
    Biochim Biophys Acta Mol Basis Dis; 2024 Aug; 1870(6):167230. PubMed ID: 38734322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The gut microbiome and liver cancer: mechanisms and clinical translation.
    Yu LX; Schwabe RF
    Nat Rev Gastroenterol Hepatol; 2017 Sep; 14(9):527-539. PubMed ID: 28676707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated analysis of microbiome and host transcriptome reveals correlations between gut microbiota and clinical outcomes in HBV-related hepatocellular carcinoma.
    Huang H; Ren Z; Gao X; Hu X; Zhou Y; Jiang J; Lu H; Yin S; Ji J; Zhou L; Zheng S
    Genome Med; 2020 Nov; 12(1):102. PubMed ID: 33225985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The gut microbiome-bile acid axis in hepatocarcinogenesis.
    Wu L; Feng J; Li J; Yu Q; Ji J; Wu J; Dai W; Guo C
    Biomed Pharmacother; 2021 Jan; 133():111036. PubMed ID: 33378947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered gut microbiota in hepatocellular carcinoma: Insights into the pathogenic mechanism and preclinical to clinical findings.
    Das BK
    APMIS; 2022 Dec; 130(12):719-740. PubMed ID: 36321381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis.
    Jiang JW; Chen XH; Ren Z; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2019 Feb; 18(1):19-27. PubMed ID: 30527903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma.
    Behary J; Amorim N; Jiang XT; Raposo A; Gong L; McGovern E; Ibrahim R; Chu F; Stephens C; Jebeili H; Fragomeli V; Koay YC; Jackson M; O'Sullivan J; Weltman M; McCaughan G; El-Omar E; Zekry A
    Nat Commun; 2021 Jan; 12(1):187. PubMed ID: 33420074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut Microbiota Promotes Obesity-Associated Liver Cancer through PGE
    Loo TM; Kamachi F; Watanabe Y; Yoshimoto S; Kanda H; Arai Y; Nakajima-Takagi Y; Iwama A; Koga T; Sugimoto Y; Ozawa T; Nakamura M; Kumagai M; Watashi K; Taketo MM; Aoki T; Narumiya S; Oshima M; Arita M; Hara E; Ohtani N
    Cancer Discov; 2017 May; 7(5):522-538. PubMed ID: 28202625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease.
    Ponziani FR; Bhoori S; Castelli C; Putignani L; Rivoltini L; Del Chierico F; Sanguinetti M; Morelli D; Paroni Sterbini F; Petito V; Reddel S; Calvani R; Camisaschi C; Picca A; Tuccitto A; Gasbarrini A; Pompili M; Mazzaferro V
    Hepatology; 2019 Jan; 69(1):107-120. PubMed ID: 29665135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer.
    Ezzaidi N; Zhang X; Coker OO; Yu J
    Cancer Lett; 2019 Sep; 459():186-191. PubMed ID: 31185249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unveiling the complex relationship between gut microbiota and liver cancer: opportunities for novel therapeutic interventions.
    Rajapakse J; Khatiwada S; Akon AC; Yu KL; Shen S; Zekry A
    Gut Microbes; 2023 Dec; 15(2):2240031. PubMed ID: 37615334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bile acids, gut microbiota, and therapeutic insights in hepatocellular carcinoma.
    Song Y; Lau HC; Zhang X; Yu J
    Cancer Biol Med; 2023 Dec; 21(2):144-62. PubMed ID: 38148326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbiota, NASH, HCC and the potential role of probiotics.
    Brandi G; De Lorenzo S; Candela M; Pantaleo MA; Bellentani S; Tovoli F; Saccoccio G; Biasco G
    Carcinogenesis; 2017 Mar; 38(3):231-240. PubMed ID: 28426878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining the temporal evolution of gut dysbiosis and inflammatory responses leading to hepatocellular carcinoma in Mdr2 -/- mouse model.
    Behary J; Raposo AE; Amorim NML; Zheng H; Gong L; McGovern E; Chen J; Liu K; Beretov J; Theocharous C; Jackson MT; Seet-Lee J; McCaughan GW; El-Omar EM; Zekry A
    BMC Microbiol; 2021 Apr; 21(1):113. PubMed ID: 33858327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonalcoholic Fatty Liver Disease and the Gut Microbiome.
    Boursier J; Diehl AM
    Clin Liver Dis; 2016 May; 20(2):263-75. PubMed ID: 27063268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.